News
ChroMedX completes HemoPalm analyzer, system prototype
2017-05-19 16:29 ET - News Release
Mr. Ash Kaushal reports
CHROMEDX COMPLETES HEMOPALM SYSTEM PROTOTYPE
ChroMedX Corp. has completed a HemoPalm hand-held analyzer and cartridge system prototype.
The HemoPalm system prototype has been developed as a collaborative effort led by ChroMedX chief executive officer and president Ash Kaushal, with key contributors internationally. The prototype system demonstrates portability and infield hand-held analysis capabilities.
"I am proud to announce this accomplishment and would like to congratulate our team and advisers on an extraordinary job. This prototype represents the significant success we have had in developing technology from a pending patent to a patented hand-held system," said Ash Kaushal, president and chief executive officer, ChroMedX.
ChroMedX commenced development of the HemoPalm system concurrently with the company's formation as a publicly traded entity in 2014. The intellectual property was written by ChroMedX founder and Director James Samsoondar to address the need for a hand-held device that offers combined blood gases, electrolyte, CO-oximetry and bilirubin analysis of blood in a single/disposable cartridge for hospital and infield applications. The technology addresses a projected $1.8-billion (U.S.) industry by 2020.
"Our dedication to the advancement of POCT health care is unwavering, and this milestone marks the culmination of a great deal of dedication and perseverance. Research and development always presents a fair share of challenges in the early stages, and it is the people behind the development that makes the difference. I commend the ChroMedX development team and the leadership of Ash Kaushal, and his accomplishments in a short time as CEO. We are very excited to move into the next stage of development and play a role in the advancement of POCT health care," said Dr. George Langdon, chairman, ChroMedX.
The assembly of the physical unit prototype includes the essential components of the HemoPalm system and a streamlined design. The current HemoPalm system design offers full CO-oximetry and bilirubin analysis capabilities, and the cartridge design includes biosensors for pH, PO2 and PCO2 (blood gases) and Na+, K+ and Cl- (electrolytes), as well as two additional sensors for future analytes, such as lactate and creatinine. Lactate assists in the detection of blood poisoning (sepsis) in life-threatening situations, and creatinine is the preferred analyte for assessing kidney function. Within this POCT system to date, the company has demonstrated operational CO-oximetry and the initial stages of operational biosensors.
Prototype analyzer and cartridge scale
The completion of the hand-held prototype system is a key step in the progression toward a preproduction device, and refinements in the design and functionality of the system will continue through the testing phase.
ChroMedX is now working toward organizing the manufacturability and reproducibility of cartridges using injection moulding instead of machining. The moulded cartridges will be used for testing, calibration and validation of the HemoPalm analyzer prototype. The company is now focused on completing all functionality and testing/calibration for clinical trials in fourth quarter 2017.
The HemoPalm hand-held blood analyzer system is protected by U.S. patent No. 9,162,186 and 8,206,650, pending PCT/CA2017/050379 and other international issued and pending patents.
About ChroMedX Corp.
ChroMedX is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the company's issued and pending patents, dealing with blood collection, analysis and plasma/serum processing.